AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
13 Settembre 2023 - 3:00PM
Business Wire
AbCellera (Nasdaq:ABCL) announced today that it has entered into
a strategic collaboration with Incyte (Nasdaq:INCY) to discover and
develop therapeutic antibodies in oncology.
“We are excited to partner with Incyte, which has a track record
of developing first-in-class medicines and bringing them to
patients in need,” said Murray McCutcheon, Ph.D., Senior Vice
President of Partnering at AbCellera. “We look forward to working
as an extension of Incyte’s team to address complex antibody
discovery challenges and accelerate the development of Incyte’s
preclinical pipeline of oncology medicines.”
“This collaboration supports our continued commitment to
developing new therapeutics that may improve and expand treatment
options for patients with cancer,” said Patrick Mayes, Ph.D., Vice
President, BioTherapeutics at Incyte. “We are excited to partner
with AbCellera to initiate this research and look forward to
collaborating with them to identify new antibody therapeutics that
may address unmet needs in oncology.”
Under the financial terms of the agreement, Incyte has the right
to develop and commercialize therapeutic antibodies resulting from
the collaboration. AbCellera will receive research payments and is
eligible to receive downstream clinical and regulatory milestone
payments and royalties on net sales of products.
About AbCellera Biologics Inc.
AbCellera is breaking the barriers of conventional antibody drug
discovery to bring better medicines to patients, sooner.
AbCellera’s engine integrates expert teams, technology, and
facilities with the data science and automation needed to propel
antibody-based medicines from target to clinic in nearly every
therapeutic area with precision and speed. AbCellera provides
innovative biotechs and leading pharmaceutical companies with a
competitive advantage that empowers them to move quickly, reduce
cost, and tackle the toughest problems in drug development. For
more information, please visit www.abcellera.com.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s current
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking statements,
including statements regarding our ability to develop,
commercialize and achieve market acceptance of our current and
planned products and services, our research and development
efforts, and other matters regarding our business strategies, use
of capital, results of operations and financial position, and plans
and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230912918216/en/
Inquiries Media: Jessica Yingling, Ph.D.;
media@abcellera.com, +1(236)521-6774 Business Development: Murray
McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005 Investor
Relations: Josephine Hellschlienger, Ph.D.; ir@abcellera.com,
+1(778)729-9116
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Giu 2023 a Giu 2024